The short answer
Ashwagandha can cause drowsiness, making extra impairment with valproate possible. A small study included valproate-treated patients but did not establish a valproate-specific sedation risk. Products and other medicines matter.
What this answer covers
Oral Withania somnifera preparations. Sensoril aqueous-extract findings do not establish the same effects for every root, leaf or mixed extract.
- Supplement or preparation
- Withania somnifera
- Medication ingredient
- valproate
Why the combination needs review
Valproate can impair alertness. NCCIH lists drowsiness from ashwagandha and possible interactions with sedatives and anticonvulsants. These support a precaution about added impairment, not a quantified probability for this pair.
What a bipolar study showed
A study of 60 stable adults added standardized ashwagandha extract or placebo to maintenance psychiatric treatment, including valproate. Adverse events overall were mild and did not differ significantly between groups. One extract recipient needed a lower study dose because of sleepiness, but the report does not link that event specifically to valproate.
What it does not establish
The study reported no significant between-group difference in valproate levels, without showing the underlying data. It was small, brief and involved mixed medicines. It neither establishes a clinically important concentration interaction nor proves safety for all ashwagandha preparations. Cognitive test findings are not evidence that the supplement treats valproate side effects.
Use the exact product in the discussion
Discuss the preparation and reason for use with the treating team before starting. Report new excessive sleepiness, confusion or unsteadiness, and avoid driving while impaired. The study dose is not a self-treatment recommendation, and no protective spacing interval was established.
Evidence and practical considerations
Side effects & toxicity
Retain a possible added-drowsiness precaution, with explicit small mixed-medication trial limits and no valproate-specific serious CNS depression demonstrated.
- Exact scope
- Oral Withania somnifera preparations. Sensoril aqueous-extract findings do not establish the same effects for every root, leaf or mixed extract. with Oral valproate active moiety (RxNorm 40254 IN), with formulation boundaries preserved.
- Medication form and route
- oral valproate; oral supplement
What remains uncertain
- Evidence does not quantify all-product interaction risk; source-specific limits apply.
Factors that may matter: Indication; Exact preparation; Other sedating medicines.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed oral valproic acid; valproate somnolence trial in elderly dementia patients.
Valproate may impair alertness, especially with other CNS depressants. Older adults may have more somnolence. Major metabolic pathways are glucuronidation and beta-oxidation; CYP oxidation is relatively minor. Serious liver injury is an intrinsic risk.
How this applies: Explicit oral active-moiety bridge to RxNorm IN 40254 valproate; no dose conversion or intravenous extrapolation.
No named interaction with the seven supplements. Active-moiety relevance does not establish identical kinetics or dosing for every valproate formulation.
Source 2: federal supplement safety guidance
nccih.nih.gov · Source check Sep 10, 2026
Population: Users of the specified supplement.
Ashwagandha can cause drowsiness and may interact with sedatives and anticonvulsants.
How this applies: Supplement-only guidance interpreted alongside the medication label.
Does not quantify a valproate interaction or establish protective dose spacing.
Source 3: original human randomized study
psychiatrist.com · Source check Sep 10, 2026
Population: 60 stable adults with bipolar disorder on maintenance medicines, including valproate.
Adverse events were mild and transient, without significant between-group difference; no serious adverse events. One extract recipient required dose reduction for sleepiness. Valproate levels did not differ significantly between groups (data not shown).
How this applies: Applies only to the stated preparation, population and measured endpoints.
Mixed maintenance medicines; no valproate-specific sedation subgroup. Small short study cannot establish rare-event or all-product safety. Three cognitive signals would not survive correction for multiple comparisons.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Prepared article with direct-study limits, preparation boundaries and claim-specific conclusions. | |
| Research summary published |
Article revision: 3a326f4ed84192e5
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.